Search results for "N.M.B."

showing 10 items of 684 documents

An Integrated Pharmacophore/Docking/3D-QSAR Approach to Screening a Large Library of Products in Search of Future Botulinum Neurotoxin A Inhibitors

2020

Botulinum toxins are neurotoxins produced by Clostridium botulinum. This toxin can be lethal for humans as a cause of botulism

0301 basic medicineModels MolecularBotulinum ToxinsDatabases FactualNeuromuscular transmissionQuantitative Structure-Activity RelationshipPharmacologymedicine.disease_cause01 natural sciencesType Alcsh:ChemistryModelsClostridium botulinumbotulinum neurotoxin ABotulismBotulinum Toxins Type Alcsh:QH301-705.5Spectroscopyfood and beveragesGeneral MedicineBotulinum neurotoxinComputer Science ApplicationsdockingPharmacophoreQuantitative structure–activity relationshipStatic ElectricityChemicalbotulinum neurotoxin A virtual screening docking 3D-QSAR molecular dynamicsMolecular Dynamics SimulationArticleCatalysisInorganic ChemistrySmall Molecule Libraries03 medical and health sciencesDatabasesmedicinePhysical and Theoretical ChemistryMolecular BiologyFactual3D-QSARVirtual screening010405 organic chemistrybusiness.industryfungiOrganic ChemistryMolecularHydrogen Bondingmedicine.diseasevirtual screeningmolecular dynamics0104 chemical sciences030104 developmental biologyModels Chemicallcsh:Biology (General)lcsh:QD1-999Docking (molecular)Clostridium botulinumbusinessInternational Journal of Molecular Sciences
researchProduct

Oleanane-type glycosides from the roots of Weigela florida “rumba” and evaluation of their antibody recognition

2018

Three triterpene glycosides were isolated from the roots of Weigela florida "rumba" (Bunge) A. DC.: two previously undescribed 3-O-β-d-xylopyranosyl-(1→2)-[β-d-xylopyranosyl-(1→4)]-β-d-xylopyranosyl-(1→4)-β-d-xylopyranosyl-(1→3)-α-L-rhamnopyranosyl-(1→2)-α-l-arabinopyranosyloleanolic acid (1) and 3-O-β-d-xylopyranosyl-(1→2)-[β-d-glucopyranosyl-(1→4)]-β-d-xylopyranosyl-(1→4)-β-d-xylopyranosyl-(1→3)-α-l-rhamnopyranosyl-(1→2)-α-L-arabinopyranosyloleanolic acid (2), and one isolated for the first time from a natural source 3-O-β-d-xylopyranosyl-(1→3)-α-l-rhamnopyranosyl-(1→2)-α-l-arabinopyranosyloleanolic acid (3). Their structures were elucidated mainly by 2D NMR spectroscopic analysis (COSY, …

0301 basic medicineMultiple SclerosisStereochemistryEnzyme-Linked Immunosorbent AssayCaprifoliaceaePlant Roots01 natural sciences03 medical and health scienceschemistry.chemical_compoundTriterpeneDrug DiscoveryHumansGlycosidesOleanolic AcidCaprifoliaceaeOleanolic acidOleananePharmacologychemistry.chemical_classificationMolecular Structurebiology010405 organic chemistryGlycosideGeneral Medicinebiology.organism_classification0104 chemical sciences030104 developmental biologyImmunoglobulin MchemistryImmunoglobulin Mbiology.proteinAntibodyTwo-dimensional nuclear magnetic resonance spectroscopyFitoterapia
researchProduct

2018

Mobile genetic elements such as conjugative plasmids are responsible for antibiotic resistance phenotypes in many bacterial pathogens. The ability to conjugate, the presence of antibiotics, and ecological interactions all have a notable role in the persistence of plasmids in bacterial populations. Here, we set out to investigate the contribution of these factors when the conjugation network was disturbed by a plasmid-dependent bacteriophage. Phage alone effectively caused the population to lose plasmids, thus rendering them susceptible to antibiotics. Leakiness of the antibiotic resistance mechanism allowing Black Queen evolution (i.e. a "race to the bottom") was a more significant factor t…

0301 basic medicinePhysiologymedicine.drug_class030106 microbiologyAntibioticsPopulationBiochemistryMicrobiologyMicrobiologyBacteriophage03 medical and health sciencesPlasmidAntibiotic resistanceGeneticsmedicineeducationMolecular BiologyEcology Evolution Behavior and Systematics2. Zero hungereducation.field_of_studybiologyResistance (ecology)biology.organism_classificationComputer Science Applications030104 developmental biologyModeling and SimulationMobile genetic elementsBacteriamSystems
researchProduct

Inoculation of airborne conidia of Penicillium chrysogenum on the surface of a solid medium

2016

International audience; To reproduce a fungal contamination of food products by airborne conidia, a method to inoculate a few number (in the range 1-9) of conidia on the surface of agar media was developed. This technique would allow to determine accurately the time to detection of fungal colonies, then the mould free shelf-life of food products by using dry conidia. The method was based on dry-harvesting the conidia in the lid by gently taping the bottom of the dishes where sporulating mycelium was grown, retaining the conidia on glass beads, and, aseptically transferring the beads to successive Petri dishes to "dilute" the samples. Among the eleven factors tested by means of an experiment…

0301 basic medicineSporesfood.ingredientSerial dilutiongrowth030106 microbiologyGerminationPenicillium chrysogenumMicrobiologyConidiumlaw.inventionMolds03 medical and health sciencesfoodPredictive mycologylaw[SDV.IDA]Life Sciences [q-bio]/Food engineeringBotanyAgarRelative-humidityskin and connective tissue diseasesMyceliumDry harvestbiologyShelf-lifeSpoilagePetri dishfungi[ SDV.IDA ] Life Sciences [q-bio]/Food engineeringPenicillium chrysogenumbiology.organism_classificationExperimental designSporeHorticultureFood productsAspergillusImpactGerminationAir-qualityFood ScienceWater activity
researchProduct

Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index

2020

We read with interest the recently published paper from McGonagle et al 1 analysing the role of interleukin (IL)-17A in axial spondyloarthritis and psoriatic arthritis (PsA). The meta-analysis and functional study provided by the authors highlighted the efficacy of IL-17A block by secukinumab in the treatment of PsA. However, there is no mention of the role of body mass index (BMI), if any, in influencing the clinical response to secukinumab, given the lack of published data. PsA is a chronic inflammatory arthritis burdened by a series of metabolic comorbidities. Among them, obesity is very common in PsA, with a prevalence of 27%, as confirmed by a recent Spanish work.2 Obesity in PsA has b…

0301 basic medicineTreatment responsemedicine.medical_specialtypsoriatic arthritiInflammatory arthritisImmunologyDMARDs (biologic)urologic and male genital diseasestreatment.General Biochemistry Genetics and Molecular Biology03 medical and health sciencesPsoriatic arthritis0302 clinical medicineRheumatologyInternal medicinemedicineImmunology and AllergyIn patient030203 arthritis & rheumatologytreatmentbusiness.industryInterleukinmedicine.diseaseObesity030104 developmental biologySecukinumabbusinessBody mass index
researchProduct

Identification and control of moulds responsible for black spot spoilage in dry-cured ham.

2016

The aims of this work were to identify moulds responsible for black spot spoilage in the drying and cellar stages of dry-cured ham processing and evaluate the effectiveness of preventive actions for controlling this alteration. Four mould strains isolated from spoiled hams were identified by morphological characteristics and the ITS and β-tubulin sequencing. Two of them were Cladosporium oxysporum, one was C. cladosporioides and the remaining one was C. herbarum. These spoiling strains reproduced the black spots on dry-cured ham-based media and ham slices. Additionally, the effect of water activity (aw) conditions reached throughout dry-cured ham ripening and the activity of the protective …

0301 basic medicinebiologyWater activityFood spoilageSus scrofaFood preservationfood and beveragesRipeningPenicillium chrysogenumbiology.organism_classificationPenicillium chrysogenumMeat Products03 medical and health sciences030104 developmental biologyFood PreservationFood MicrobiologyFood microbiologyAnimalsMicrobial InteractionsFood scienceDesiccationCladosporiumFood ScienceBlack spotCladosporiumMeat science
researchProduct

IL-17 for therapy.

2017

The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. The forerunner Secukinumab, an IL-17A neutralizing antibody, is meanwhile approved as first-line treatments for moderate-to-severe plaque psoriasis, and as second-line treatment for psoriatic arthritis and ankylosing spondylitis. Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also recently approved by the FDA for plaque psoriasis. Using mice overexpressing IL-17A in a tissue of choice, we showed that the ectopic expression of this cytokine in keratinocytes resulted in a spontaneous and very strong form of psoriasis-like dermatitis…

0301 basic medicinemedicine.drug_classBrodalumabDermatitisMice TransgenicDermatologyMonoclonal antibodymedicine.disease_causeAntibodies Monoclonal HumanizedBiochemistryAutoimmunity03 medical and health sciencesPsoriatic arthritisMice0302 clinical medicinePsoriasisMedicineAnimalsHumansPsoriasisSpondylitis AnkylosingMolecular Targeted TherapyMolecular BiologySkinbusiness.industryInterleukin-17Antibodies Monoclonalmedicine.diseaseIxekizumabDisease Models Animal030104 developmental biologyImmunologySecukinumabInterleukin 17business030215 immunologySignal TransductionJournal of dermatological science
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

THU0569 MANAGEMENT OF ADULT-ONSET STILL’S DISEASE (AOSD) WITH IL-1 INHIBITORS: EVIDENCE- AND CONSENSUS-BASED STATEMENTS BY A PANEL OF ITALIAN EXPERTS

2019

Background: Still’s disease is a rare autoinflammatory disease, presenting in both pediatric [systemic juvenile idiopathic arthritis (SJIA)] and adult patients [adult-onset Still’s disease (AOSD]. Due to the rarity of the disease, clinical trials are limited and treatment guidelines are not available. In patients refractory to the classical therapy with NSAIDs, corticosteroids and DMARDs, the introduction of drugs targeting IL-1 has greatly expanded treatment options. Among these, canakinumab, a human monoclonal anti-IL-1β antibody, and anakinra, a human recombinant IL-1RA, have been recently approved for the treatment of refractory patients. Objectives: To produce recommendations, based on…

030203 arthritis & rheumatology0301 basic medicinemedicine.medical_specialtyAnakinraAdult-onset Still's diseaseAdult patientsbusiness.industryTreatment optionsBiologic treatmentClinical trial03 medical and health sciencesCanakinumab030104 developmental biology0302 clinical medicineFamily medicinemedicineIn patientbusinessmedicine.drugPoster Presentations
researchProduct

The effective and safe method for preventing and treating bacteria-induced dental diseases by herbal plants and a recombinant peptide

2020

Background This study was conducted aimed at evaluating the antibacterial property of the recombinant peptide of bacteriocin entrocin P (EnP), the essential oil of Cuminum cyminum, and the extract of Ferulago angulata on some oral pathogens. Besides, the cytotoxicity of EnP was evaluated. Material and methods The antimicrobial property was tested on streptococcus mutans (ATCC 35668), streptococcus salivarius (ATCC 9222), streptococcus oralis (ATCC 35037), and Enterococcus faecalis (ATCC 29212), using the microbroth dilution method. The 0.2% Chlorhexidin (CHX) mouthwash was used as the control group. Besides, the cytotoxicity analysis was done on gingival fibroblasts by the MTT colorimetric …

030213 general clinical medicineCuminumbiologyTraditional medicineChemistryResearchChlorhexidine030206 dentistryEsthetic Dentistrybiology.organism_classificationAntimicrobial:CIENCIAS MÉDICAS [UNESCO]Streptococcus mutansEnterococcus faecalislaw.invention03 medical and health sciences0302 clinical medicineStreptococcus oralisStreptococcus salivariuslawUNESCO::CIENCIAS MÉDICASmedicineGeneral DentistryEssential oilmedicine.drug
researchProduct